James, Nicholas D ;
Sydes, Matthew R ;
Clarke, Noel W...
James , N D , Sydes , M R , Clarke , N W , Mason , M D , Dearnaley , D P , Spears , M R , Ritchie , A W S , Parker , C C , Russell , J M , Attard , G , de Bono , J , Cross , W , Jones , R J , Thalmann , G , Amos , C , Matheson , D , Millman , R , Alzouebi , M , Beesley , S , Birtle , A J , Brock , S , Cathomas , R , Chakraborti , P , Chowdhury , S , Cook , A , Elliott , T , Gale , J , Gibbs , S , Graham , J D , Hetherington , J , Hughes , R , Laing , R , McKinna , F , McLaren , D B , O'Sullivan , J M , Parikh , O , Peedell , C , Protheroe , A , Robinson , A J , Srihari , N , Srinivasan , R , Staffurth , J , Sundar , S , Tolan , S , Tsang , D , Wagstaff , J , Parmar , M K B & STAMPEDE investigators 2016 , ' Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial ' , Lancet , vol. 387 , no. 10024 , pp. 1163–117....
,
2016
